Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.44 |
| ▸ | KHK | P50053 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 1/20 | 0.41 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622707 | 0.95 | FFAR4 (0.45) | FFAR4KHK | |
| SCHEMBL1025117 | 0.85 | ALDH1A1 (0.36) | FFAR4KHKFFAR1GPR6EIF4EBP1 | |
| Trifluoroacetic Acid SCHEMBL1022986 | 0.80 | FFAR4 (0.48) | FFAR4KHKFFAR1EIF4EBP1 | |
| SCHEMBL13670106 | 0.78 | FFAR4 (0.46) | FFAR4 | |
| Trifluoroacetic Acid SCHEMBL1023728 | 0.76 | KDM4E (0.58) | FFAR4FFAR1 | |
| Trifluoroacetic Acid SCHEMBL1023807 | 0.74 | ALDH1A1 (0.60) | FFAR4KHK | |
| Trifluoroacetic Acid SCHEMBL1024810 | 0.74 | FFAR4 (0.55) | FFAR4FFAR1 | |
| SCHEMBL13622690 | 0.72 | HRH4 (0.51) | FFAR4KHKFFAR1 | |
| Trifluoroacetic Acid SCHEMBL4357612 | 0.72 | FFAR4 (0.59) | FFAR4FFAR1EIF4EBP1 | |
| Trifluoroacetic Acid SCHEMBL1025132 | 0.71 | FFAR4 (0.46) | FFAR4KHKFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | FFAR4 2075/4885KHK 2042/4885FFAR1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.